Clinical Trial Update: Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing the HERV-W Env antagonist GNbAC1 for efficacy in relapsing-remitting multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis Relapsing-remitting

Drugs mentioned

• GNbAC1

Snippet

Sponsor: GeNeuro SA | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 2 | Status: COMPLETED